AChE

Updated data from GARNET cohort F evaluating Dostarlimab in mismatch repair-deficient ( dMMR ) non-endometrial advanced solid cancers were presented at...


The European Commission ( EC ) has approved Rinvoq ( Upadacitinib, 15 mg ), an oral, once daily selective and...


The FDA ( U.S. Food and Drug Administration ) has approved Opdivo ( Nivolumab ) 240 mg injection for intravenous...


The European Commission ( EC ) has approved Bavencio ( Avelumab ) as monotherapy for the first-line maintenance treatment of...


EMA ( European Medicines Agency ) has recommended granting a conditional marketing authorisation for COVID-19 Vaccine AstraZeneca to prevent coronavirus...


The Food and Drug Administration ( FDA ) has approved Xalkori ( Crizotinib ) for pediatric patients 1 year of...


The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...


The U.S. Food and Drug Administration ( FDA ) has approved Breyanzi ( Lisocabtagene maraleucel; Liso-cel ), a CD19-directed chimeric...


The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...


New data from the phase 1 CHRYSALIS study, which has evaluated Amivantamab in patients with metastatic or unresectable non-small cell...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Ukoniq ( Umbralisib ), a kinase inhibitor...


The FDA ( U.S. Food and Drug Administration ) has issued an emergency use authorization ( EUA ) for the...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Yescarta ( Axicabtagene ciloleucel ) for...


EMA’s safety committee, PRAC, has concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19...


The FDA ( U.S. Food and Drug Administration ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and...


The FDA ( U.S. Food and Drug Administration ) has approved Abecma ( Idecabtagene vicleucel; Ide-cel ) as the first...


EMA’s safety committee ( PRAC ) has concluded that a warning about unusual blood clots with low blood platelets should...


Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...